Results
The number of surgical treatments for RCC during the COVID-19 pandemic
has decreased significantly compared to the same period before COVID-19.
No significant differences were found between the two periods in terms
of admission symptoms (p=0.32). However, while the rate of application
due to hematuria was 6.1% in the pre-COVID-19 period, it was 13.1%
during the COVID-19 period. Despite not being significant, this
difference was still proportional. Two study periods differed
significantly in terms of the rate of metastatic RCC detected in
preoperative imaging (13.1% vs 6.1%, during COVID-19 and pre-COVID-19,
respectively) (p=0.01). Moreover, the study periods differed
significantly in terms of time between imaging and operation
(55.98±51.02 vs 40.30±34.9 days, during COVID-19 and pre-COVID-19,
respectively) (p=0.01). However, there was no significant difference
between the two periods in terms of tumor size, type of surgery, and
pathological stage (p>0.05).